Vivanza Biosci.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE984E01035
  • NSEID:
  • BSEID: 530057
INR
1.66
0.22 (15.28%)
BSENSE

Nov 20

BSE+NSE Vol: 71.09 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 515837,
    "name": "Vivanza Biosci.",
    "stock_name": "Vivanza Biosci.",
    "full_name": "Vivanza Biosciences Ltd",
    "name_url": "stocks-analysis/vivanza-biosci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1.66",
    "chg": 0.22,
    "chgp": "15.28%",
    "dir": 1,
    "prev_price": "1.44",
    "mcapval": "6.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530057,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE984E01035",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "71.09 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vivanza Biosciences Falls 5.88%: 3 Key Factors Behind the Weekly Decline",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/vivanza-biosciences-falls-588-3-key-factors-behind-the-weekly-decline-4237529",
        "imagepath": "",
        "date": "2026-10-24 17:03:38",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>19 Oct:</strong> Stock hits 52-week low at Rs.1.41 amid sharp 17.06% drop</p>\n                    <p><strong>19 Oct:</strong> Mojo Grade upgraded from Strong Sell to Sell on technical improvement</p>\n                    <p><strong>21 Oct:</strong> Downgraded back to Strong Sell following technical deterioration</p>\n                    <p><strong>23 Oct:</strong> Week closes at Rs.1.60, down 5.88% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.70</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div..."
      },
      {
        "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.41 as Sell-Off Deepens",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/vivanza-biosciences-ltd-stock-hits-52-week-low-amidst-continued-underperformance-4230369",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/VivanzaBioscien_priceRelatedfactors_4230369.png",
        "date": "2026-10-19 11:41:59",
        "description": "A sharp decline of 17.06% in a single session has dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.41 on 19 Oct 2026, extending a prolonged period of underperformance against the broader market indices."
      },
      {
        "title": "Vivanza Biosciences Ltd Upgraded to Sell on Technical Improvement Despite Lingering Fundamental Challenges",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-on-technical-improvement-despite-lingering-fundamental-challenges-4229686",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/VivanzaBioscien_mojoScore_4229686.png",
        "date": "2026-10-19 08:13:29",
        "description": "Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Oct 2026, driven primarily by a shift in technical indicators. Despite this improvement, the pharmaceutical micro-cap continues to face significant fundamental headwinds, including operating losses and weak long-term growth prospects, which temper investor enthusiasm."
      },
      {
        "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Weak Technicals and Financial Strain",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-weak-technicals-and-financial-strain-4222298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/VivanzaBioscien_mojoScore_4222298.png",
        "date": "2026-10-12 08:08:38",
        "description": "Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 09 Oct 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s overall outlook has worsened due to bearish technical trends, weak long-term financial strength, and consistent underperformance against market benchmarks."
      }
    ],
    "total": 28,
    "sid": "515837",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/vivanza-biosciences-515837"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-Nov-2026",
      "details": "in terms of Regulation 47 of the SEBI(LODR) Reg 2015 please find copy of the newspaper publication in the English and vernacular language of the state wherein the Unaudited Standalone and Consolidated financial Statements for the Quarter ended September 30 2026 published.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited Held On 06.11.2026",
      "datetime": "06-Nov-2026",
      "details": "Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday 06th November 2026 at the Registered Office of the Company has inter alia considered and approved the following businesses:",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Pursuant To Regulation 29 & 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "03-Nov-2026",
      "details": "Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter and Half year ended September 30 2026 and Any other business with the permission of the chair",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23",
          "dt": "2023-03-24",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

07-Nov-2026 | Source : BSE

in terms of Regulation 47 of the SEBI(LODR) Reg 2015 please find copy of the newspaper publication in the English and vernacular language of the state wherein the Unaudited Standalone and Consolidated financial Statements for the Quarter ended September 30 2026 published.

Board Meeting Outcome for Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited Held On 06.11.2026

06-Nov-2026 | Source : BSE

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday 06th November 2026 at the Registered Office of the Company has inter alia considered and approved the following businesses:

Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Pursuant To Regulation 29 & 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

03-Nov-2026 | Source : BSE

Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter and Half year ended September 30 2026 and Any other business with the permission of the chair

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Vivanza Biosciences Ltd has announced 1:10 stock split, ex-date: 24 Mar 23

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available